HCPCS Level II · Drugs administered other than oral method
J9271Injection, pembrolizumab, 1 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J9271
J9271 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, pembrolizumab, 1 mg.
It was added to HCPCS effective 01/01/2016.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj pembrolizumab
- Date added
- 01/01/2016
- Action effective
- 01/01/2016
- BETOS
- O1D
Related J92xx codes
- J9200Injection, floxuridine, 500 mg
- J9201Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
- J9202Goserelin acetate implant, per 3.6 mg
- J9203Injection, gemtuzumab ozogamicin, 0.1 mg
- J9204Injection, mogamulizumab-kpkc, 1 mg
- J9205Injection, irinotecan liposome, 1 mg
- J9206Injection, irinotecan, 20 mg
- J9207Injection, ixabepilone, 1 mg
- J9208Injection, ifosfamide, 1 gram
- J9209Injection, mesna, 200 mg
- J9210Injection, emapalumab-lzsg, 1 mg
- J9211Injection, idarubicin hydrochloride, 5 mg
Common questions about J9271
Is HCPCS J9271 still valid?
- Yes. J9271 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J9271?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.